Biogen CEO Michel Vounatsos admitted Thursday that the launch of Aduhelm, the company’s intensely scrutinized treatment for Alzheimer’s disease, has been “slower than we anticipated,” which he blamed in part on “confusion, misinformation, and controversy” about whether the drug works and how it was approved.
Only about 50 centers around the country have administered at least one dose of Aduhelm, which won Food and Drug Administration approval on June 7, Biogen said at an investor conference sponsored by the investment bank Morgan Stanley. That has led Biogen to revisit its “already very low sales target” for 2021, Vounatsos said.
Create a display name to comment
This name will appear with your comment